Circulating s-Endoglin concentrations in non-obese patients with gestational diabetes mellitus

• Published in: Journal of obstetrics and gynaecology p. 1
• Main Authors: Nergiz Avcıoğlu, Sümeyra, Demircan Sezer, Selda, Altınkaya, Sündüz Özlem
• Format: Journal Article
• Language: English
• Published: England 04.07.2022
• Subjects: s-Endoglin; insulin resistance markers; non-obese-gestational diabetes mellitus
• ISSN: 1364-6893
• DOI: 10.1080/01443615.2021.2012436

The aim of this study was to compare maternal concentrations of soluble Endodlin (s-Endoglin) in women with gestational diabetes (GDM) and women with normal glucose tolerance (NGT) in pregnancy. Also, the association of insulin resistance markers and s-Endoglin was investigated. Forty patients complicated by GDM and forty gestational age-matched healthy pregnant women with NGT were included in the present study. s-Endoglin level was higher in patients with GDM compared with the control group ( .01). Besides a positive correlation was found between s-Endoglin and fasting glucose (  = 0.206,  = .057), insulin (  = 0.302,  = .005), HbA1c (  = 0.376,  < .01), HOMA-IR values (  = 0.283,  = .008) in pregnant women included in the study. s-Endoglin, as an anti-angiogenic marker seemed to have a role in pathogenesis and significantly associated with insulin resistance markers in non-obese GDM, thus may play important roles in the regulation of glucose hemostasis.Impact Statement In women with GDM, hyperglycaemia induced glycosylation products might cause oxidative stress that may be subsequently involved in the release of inflammatory mediators, inducing angiogenesis s-Endoglin has an anti-angiogenic effect and is a useful marker of endothelial injury, activation of inflammation, senescence and oxidative stress, we speculate that it may be involved in the pathogenesis of GDM. s-Endoglin seemed to have a role in the regulation of glucose hemostasis. Further exploration of novel factors like s-endoglin in the pathogenesis of GDM, is essential and valuable to develop new therapeutic strategies for this complex disease and its complications.